

**ATTORNEY DOCKET NO. 14014.0312  
PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of )

Kelsall et al. )

Serial No. 09/196,867 )

Filed: November 20, 1998 )

For: METHODS OF USING CR3 AND CR4  
LIGANDS FOR INHIBITING  
INTERLEUKIN-12 TO TREAT  
AUTOIMMUNE DISEASE )

Group Art Unit: 1644

Examiner: DeCloux, A.

**RECEIVED**

NOV 16 1999

**GROUP 1800**

#8  
M.G.J.  
11/29/99

**ELECTION UNDER RESTRICTION REQUIREMENT**

**VIA FACSIMILE TRANSMISSION**

**703/305-3704**

ATTN: Examiner A. DeCloux

Group Art Unit 1644

Assistant Commissioner for Patents

Washington, D.C. 20231

NEEDLE &amp; ROSENBERG, P.C.

Suite 1200, The Candler Building

127 Peachtree Street, N.E.

Atlanta, Georgia 30303-1811

November 15, 1999

Sir:

This is in response to the Office Action dated September 17, 1999, wherein restriction of the claims of the above-identified application is required. The Office Action requires restriction to one of the following three groups of claims:

Group I: Claims 1-11, drawn to a method of downregulating IL-12 with CR3/4 ligands.

Group II: Claim 12, drawn to a method of screening a substance for its ability to downregulate IL-12 upon binding CR3.

Group III: Claim 13, drawn to a method of screening a substance for its ability to